Gilead Sciences Inc. (GILD)

• Annual Data
• Quarterly Data

Gilead Sciences Inc., Consolidated Statement of Financial Position, Assets

USD $ in millions

Based on: 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-25), 10-K (filing date: 2014-02-25).

---

Assets, Selected Items

Item	Description	The company
Current assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Gilead Sciences Inc.’s current assets declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.
Property, plant and equipment, net	Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.	Gilead Sciences Inc.’s property, plant and equipment, net increased from 2015 to 2016 and from 2016 to 2017.
Noncurrent assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.	Gilead Sciences Inc.’s noncurrent assets increased from 2015 to 2016 and from 2016 to 2017.
Total assets	Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Gilead Sciences Inc.’s total assets increased from 2015 to 2016 and from 2016 to 2017.

---

Current Assets, Selected Items

Item	Description	The company
Cash and cash equivalents	Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.	Gilead Sciences Inc.’s cash and cash equivalents declined from 2015 to 2016 and from 2016 to 2017.
Short-term marketable securities	Amount of investment in marketable security, classified as current.	Gilead Sciences Inc.’s short-term marketable securities increased from 2015 to 2016 and from 2016 to 2017.
Accounts receivable, net of allowances	Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.	Gilead Sciences Inc.’s accounts receivable, net of allowances declined from 2015 to 2016 and from 2016 to 2017.
Inventories	Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.	Gilead Sciences Inc.’s inventories declined from 2015 to 2016 and from 2016 to 2017.